A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor

Cet article présente le développement d'un vecteur lentiviral pour la production de lymphocytes CAR-T comportant un transgène inductible et exprimant de manière constitutive un récepteur antitumoral

Nature Biomedical Engineering, sous presse, 2023, article en libre accès

Résumé en anglais

Vectors that facilitate the engineering of T cells that can better harness endogenous immunity and overcome suppressive barriers in the tumour microenvironment would help improve the safety and efficacy of T-cell therapies for more patients. Here we report the design, production and applicability of T-cell engineering of a lentiviral vector leveraging an antisense configuration and comprising a promoter driving the constitutive expression of a tumour-directed receptor and a second promoter enabling the efficient activation-inducible expression of a genetic payload. The vector allows for the delivery of a variety of genes to human T cells, as we show for interleukin-2 and a microRNA-based short hairpin RNA for the knockdown of the gene coding for haematopoietic progenitor kinase 1, a negative regulator of T-cell-receptor signalling. We also show that a gene encoded under an activation-inducible promoter is specifically expressed by tumour-redirected T cells on encountering a target antigen in the tumour microenvironment. The single two-gene-encoding vector can be produced at high titres under an optimized protocol adaptable to good manufacturing practices.